Cara Therapeutics Inc
NASDAQ:TVRD

Watchlist Manager
Cara Therapeutics Inc Logo
Cara Therapeutics Inc
NASDAQ:TVRD
Watchlist
Price: 4.33 USD 4.59%
Market Cap: 40.6m USD

Wall Street
Price Targets

TVRD Price Targets Summary
Cara Therapeutics Inc

Wall Street analysts forecast TVRD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TVRD is 15.15 USD with a low forecast of 4.04 USD and a high forecast of 54.6 USD.

Lowest
Price Target
4.04 USD
7% Downside
Average
Price Target
15.15 USD
250% Upside
Highest
Price Target
54.6 USD
1 161% Upside
Cara Therapeutics Inc Competitors:
Price Targets
OCS
Oculis Holding AG
124% Upside
128940
Hanmi Pharm Co Ltd
9% Upside
1J5
Hyphens Pharma International Ltd
26% Upside
VETO
Vetoquinol SA
11% Upside
002603
Shijiazhuang Yiling Pharmaceutical Co Ltd
8% Upside
IPCALAB
IPCA Laboratories Ltd
15% Upside
688176
Jiangsu Yahong Meditech Co Ltd
14% Downside
AVDL
Avadel Pharmaceuticals PLC
0% Downside

Revenue
Forecast

Revenue Estimate
Cara Therapeutics Inc

For the last 8 years the compound annual growth rate for Cara Therapeutics Inc's revenue is 70%. The projected CAGR for the next 3 years is 39%.

70%
Past Growth
39%
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Cara Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
3%
Average Beat

Net Income
Forecast

Net Income Estimate
Cara Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-13%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is TVRD's stock price target?
Price Target
15.15 USD

According to Wall Street analysts, the average 1-year price target for TVRD is 15.15 USD with a low forecast of 4.04 USD and a high forecast of 54.6 USD.

What is Cara Therapeutics Inc's Revenue forecast?
Projected CAGR
39%

For the last 8 years the compound annual growth rate for Cara Therapeutics Inc's revenue is 70%. The projected CAGR for the next 3 years is 39%.

Back to Top